New Mounjaro Kwikpen 2026: What Patients Need to Know

If you’re using Mounjaro (tirzepatide) for weight management or type 2 diabetes, you may notice that your pen looks a little different from April 2026 onwards. Eli Lilly is introducing a redesigned Mounjaro KwikPen which while it works in exactly the same way, there are a few visual and structural changes worth knowing about.

Mounjaro is FDA approved for the treatment of type 2 diabetes and received FDA approval on May 13, 2022. The UK MHRA authorised Mounjaro, on 8th November 2023, for weight loss and weight management in adults aged 18 and over, covering patients with a BMI of 30 kg/m² or more (obesity), and those with a BMI of 27–30 kg/m² (overweight) who also have weight-related health problems such as prediabetes, high blood pressure, high cholesterol, or heart problems.

Here’s everything you need to know about the new Mounjaro KwikPen, what’s been updated, and how the transition will work.

Why Is Eli Lilly Updating the Mounjaro KwikPen?

The redesign has two key goals:

1. to reduce the amount of leftover medicine in the pen after use, and;
2. to make it clearer when the final dose has been delivered so patients know exactly when their pen is ready to be discarded.

These improvements are about enhancing the patient experience and reducing medicine waste, not about changing the drug itself. The active ingredient, dose strength, and injection process all remain the same.

What’s Different About the New Mounjaro KwikPen?

The modified KwikPen introduces three main visual and structural updates. Mounjaro KwikPen is designed for convenient weekly injections. These Mounjaro pens are intended to make administration simple and reliable for patients.

1. New Plunger Position

On the new pen, the plunger sits farther down in the cartridge when the pen is unused. This is completely normal and expected. It is not a sign that the pen has been used or is defective.

2. Extended Plunger Component and Injection Site

A new internal component has been added behind the plunger to extend its length. This internal change is shown in the updated Instructions For Use (IFU) guide and is what enables the pen to deliver doses more efficiently with less residual medicine remaining.

3. Clearer End-of-Pen Indicator

After the fourth and final dose has been administered, the plunger will be visibly near the end of the pen, providing a clear, unmistakable signal that the pen is empty and ready for safe disposal. After your last dose, place the used Mounjaro pen in a sharps container for safe disposal. Do not throw away the used Mounjaro pen in your household trash.

 

Does the New Pen Work the Same Way?

Yes. Mounjaro KwikPens are disposable, multi-dose, single-patient-use pre-filled pens. Both contain enough solution for priming before each injection, plus four fixed 0.6 mL doses, administered once weekly.

In the United States, Mounjaro is available in several forms, including a single dose pen, multi dose vial, and single dose vial. The KwikPen is a multi-dose pre-filled pen, but other formats may be available depending on supply and your prescription.

Before using the pen, always read the Instructions for Use and Medication Guide carefully. Wash your hands before preparing for your Mounjaro injection, and check the pen label to ensure you have the correct medicine and current dose.

You can inject Mounjaro in your abdomen (stomach), thigh, or the back of your upper arm. Rotate your injection site each week to avoid skin problems, and remember that the upper arm is a suitable site. Do not mix insulin with Mounjaro in the same injection, and do not inject different medications at the same injection site.

It is important to follow a regular dosing schedule. If you miss a dose, take it as soon as you remember unless it is more than 4 days late; if more than 4 days have passed, skip the missed dose and take your next dose at the regular time. Mounjaro should not be injected more than once every 3 days.

Your healthcare provider will start you on a low starting dose and may increase your dose every 4 weeks based on your response, blood sugar levels, and other factors. Do not exceed the maximum dose of 15 mg. Always consult your care team before making any dose increase or adjustment.

Store your Mounjaro pen in the refrigerator. Do not freeze. Keep it in the original carton to protect it from light. If needed, Mounjaro can be stored at room temperature below 30°C (86°F) for up to 21 days.

Dispose of opened vials and used pens after use, even if medication remains. Discard any unopened vials or pens after the expiration date. Never share your Mounjaro pen with anyone, even if the needle is changed.

Potential Side Effects and Risks

Like all prescription medicines, Mounjaro can cause side effects. Most people tolerate Mounjaro injections well, but it’s important to be aware of possible reactions and know when to seek medical attention.

Common side effects may include nausea, vomiting, diarrhea, decreased appetite, constipation, and mild stomach problems. These effects are usually temporary and may improve as your body adjusts to the medication. If you experience persistent or severe stomach pain, especially in the upper stomach, or if your skin or eyes become slightly yellow or dark yellow, contact your healthcare professional promptly.

Low blood sugar (hypoglycemia) can occur, especially if you take Mounjaro with other diabetes medicines like insulin or sulfonylureas. Symptoms of low blood sugar levels include shakiness, sweating, blurred vision, trouble concentrating, and feeling faint. Always keep glucose tablets or a sugary snack on hand, and talk to your healthcare provider about how to manage low blood sugar, especially if you drink alcohol or have a history of blood sugar control issues.

Serious allergic reactions are rare but can happen. Signs include rash, itching, swelling, trouble breathing, or trouble swallowing. If you notice any of these symptoms after your injection, seek immediate medical attention.

Other risks include possible thyroid tumors, including medullary thyroid carcinoma, and gallbladder problems. Let your healthcare provider know if you or anyone in your family has a personal or family history of thyroid cancer or multiple endocrine neoplasia syndrome type 2. Mounjaro may also increase the risk of kidney problems, especially if you have existing kidney disease or become dehydrated. Drink fluids regularly and report any signs of kidney issues, such as changes in urination or swelling.

Special considerations: Elderly patients, those with diabetic retinopathy, or people with a history of severe stomach problems or problems digesting food should use Mounjaro with caution. If you are pregnant, planning to become pregnant, or breastfeeding, discuss the potential risks to your unborn baby or breast milk with your healthcare provider. Mounjaro may also affect how birth control pills work, especially if you experience vomiting or diarrhea.

Always inform your healthcare professional about your full medical history and any other medicines you are taking, including over-the-counter drugs and supplements. Read the medication guide provided with your pen for a complete list of side effects and instructions on what to do if you miss a dose or experience any unusual symptoms.

If you have any concerns about side effects or risks while taking Mounjaro, contact your healthcare provider or pharmacist for advice. Your safety and well-being are the top priority as you work towards better blood sugar control and weight loss.

When Will the New Mounjaro Pen Be Available in the UK?

Eli Lilly anticipates the modified KwikPen will begin arriving in the UK from April 2026. The rollout will be gradual, once existing stock of the original pen is used up, pharmacies will transition to the new design. During this period, both versions may be in circulation across all dose strengths.

What Should Mounjaro Patients Do About the Introduction of the New Pen?

If you’re currently on Mounjaro, here’s what to keep in mind:

• Don’t be alarmed if your new pen looks different, the lower plunger position and slightly different appearance are intentional design updates, not errors.
• Read the updated Instructions For Use (IFU) included with your pen if you receive the new version, as the Guide to Parts section has been updated.
• Continue ordering as normal, there is no action required from patients or healthcare providers.
• Contact your pharmacist or prescriber if you have any concerns about your pen before use.

Frequently Asked Questions About the Mounjaro Pen Update and Side Effects

Is the new Mounjaro KwikPen safe to use?

Yes. The modified pen has been reviewed by Eli Lilly and works in the same way as the original device. The update is a device improvement, not a change to the medicine.

Why does my Mounjaro pen look different?

From April 2026, Eli Lilly is rolling out a redesigned KwikPen with a lower plunger starting position and an internal extended plunger component. These changes help reduce wasted medicine and make it easier to tell when all doses have been administered.

Do I need a new prescription for the updated Mounjaro pen?

No. Your existing prescription remains valid. The product codes are unchanged, so pharmacies will dispense the updated pen automatically as stock transitions.

Will I receive the old or the new Mounjaro pen?

During the transition period, both versions will be available in pharmacies across all dose strengths. You may receive either version depending on your pharmacy’s current stock.

Get Mounjaro for Weight Loss Through NowPatient

NowPatient is a regulated UK online pharmacy and digital health platform offering Mounjaro prescriptions through a fully supervised weight management program. Our clinical team is on hand to answer any questions about your medication or device, including updates like this one.

If you have any concerns about your Mounjaro pen or your weight loss programme, speak to your NowPatient prescriber or contact our pharmacy team directly.